Pan02 (Panc02) Syngeneic Model Overview
The Pan02 (also known as Panc02) syngeneic model is a well-characterized murine pancreatic adenocarcinoma system derived from a chemically induced ductal carcinoma in C57BL/6 mice. It is one of the most commonly used models for preclinical evaluation of pancreatic cancer immunotherapy and combination treatment approaches. Pan02 tumors exhibit aggressive, locally invasive growth with a desmoplastic stroma that closely resembles human pancreatic ductal adenocarcinoma (PDAC).
When implanted subcutaneously or orthotopically into the pancreas, Pan02 cells form dense, fibrotic tumors that demonstrate strong stromal interaction and limited natural immunogenicity. This model provides a reliable system for studying immune evasion, macrophage polarization, and tumor–stroma crosstalk in pancreatic cancer. Because of its poor baseline response to immunotherapy, Pan02 serves as a translationally relevant platform for evaluating strategies designed to overcome immune resistance in PDAC.
Request a Custom Quote for Pan02 (Panc02) Syngeneic ModelBiological and Molecular Characteristics
The Pan02 cell line was derived from a C57BL/6 mouse treated with a carcinogenic agent that induces pancreatic ductal adenocarcinoma formation. It displays an epithelial morphology with tightly packed polygonal cells and forms cohesive, poorly differentiated tumors. The molecular profile of Pan02 includes upregulation of pro-fibrotic and immunosuppressive mediators such as TGF-beta, VEGF, and IL-10, which promote stromal deposition and limit immune cell infiltration.
Pan02 tumors are characterized by low mutational burden and weak antigen presentation, resulting in minimal spontaneous T-cell activation. The tumor microenvironment is dominated by myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, and fibroblasts, all of which contribute to immune suppression and therapy resistance. These features collectively make Pan02 a rigorous model for developing and testing immune-stimulatory and stromal-targeted therapeutic strategies.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Chemically induced pancreatic ductal adenocarcinoma (mouse) |
| Histological type | Poorly differentiated adenocarcinoma |
| Inoculation route | Subcutaneous or orthotopic (pancreatic) |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Moderate; local invasion and occasional liver metastases |
| Immunophenotype | Low immunogenicity; macrophage- and fibroblast-rich microenvironment |
| Common applications | Immunotherapy, stromal targeting, fibrosis, macrophage modulation studies |
In Vivo Model Development and Tumorigenicity
Pan02 tumors are established through subcutaneous or orthotopic implantation of tumor cells into immunocompetent C57BL/6 mice. Subcutaneous inoculation produces measurable tumors within 7–10 days and allows for direct monitoring of growth kinetics and treatment response. Orthotopic implantation into the pancreas generates tumors that more closely mimic human PDAC, characterized by extensive fibrosis, invasive growth, and localized immune suppression.
This model’s poor immunogenicity and dense stromal composition make it particularly useful for testing therapies that enhance immune infiltration, disrupt fibrotic barriers, or inhibit myeloid cell recruitment. Because Pan02 tumors recapitulate many of the histopathological and molecular hallmarks of human pancreatic cancer, they serve as a translationally relevant tool for studying mechanisms of therapeutic resistance and immune modulation in a realistic tumor microenvironment.
Request a Custom Quote for Pan02 (Panc02) Syngeneic ModelHistopathology and Immunohistochemical Profile
Histological analysis of Pan02 tumors reveals irregular glandular and solid structures composed of epithelial cells with large nuclei and prominent nucleoli. The tumors are surrounded by a collagen-rich stroma containing fibroblasts, macrophages, and scattered lymphocytes. The extensive desmoplasia observed in Pan02 tumors parallels that of human pancreatic cancer, contributing to hypoxia and poor drug penetration.
Immunohistochemical staining demonstrates strong expression of cytokeratin, confirming epithelial origin, and moderate Ki-67 positivity, reflecting active but uneven proliferation. F4/80 and CD11b staining highlight abundant macrophage and myeloid cell infiltration, while CD3 and CD8 staining show sparse T-cell presence. PD-L1 expression is moderate and can be upregulated following interferon exposure or immune checkpoint inhibition. This histological and immunological landscape accurately models the immune exclusion and stromal barrier properties of pancreatic ductal adenocarcinoma.
Preclinical Applications and Drug Response
The Pan02 syngeneic model is extensively used for preclinical research in pancreatic cancer immunotherapy, fibrosis targeting, and combination therapy development. Due to its low immunogenicity, Pan02 is considered an immune-cold tumor model, making it ideal for testing interventions designed to convert non-responsive tumors into immunologically active ones. The model has been applied to studies involving checkpoint inhibitors, cytokine therapies, oncolytic viruses, and T-cell agonists, as well as stromal-modulating agents such as hyaluronidase and TGF-beta inhibitors.
Chemotherapy agents like gemcitabine and oxaliplatin have demonstrated modest efficacy in Pan02, often serving as backbones for combination studies with immunotherapeutics. This model’s resistance to monotherapy and its immunosuppressive microenvironment provide a challenging yet translationally realistic setting for developing next-generation treatment strategies. Pan02 remains one of the most relevant murine systems for modeling the complexity of human pancreatic cancer and testing therapies aimed at overcoming stromal and immune barriers.
Request This Model
To request the Pan02 (Panc02) syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for Pan02 (Panc02) Syngeneic Model